HC Wainwright Reaffirms Neutral Rating for Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “neutral” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports.

Separately, Stifel Nicolaus reduced their price target on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Trading Up 0.8 %

Bolt Biotherapeutics stock traded up $0.00 during trading hours on Tuesday, reaching $0.44. The company had a trading volume of 197,162 shares, compared to its average volume of 119,987. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.56. The company has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.56. The firm has a market cap of $16.88 million, a price-to-earnings ratio of -0.26 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Equities analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $42,000. Velan Capital Investment Management LP purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $27,000. Squarepoint Ops LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at $26,000. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter worth about $25,000. Finally, FMR LLC boosted its stake in Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after purchasing an additional 28,773 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.